Brivanib, a promising tyrosine kinase inhibitor, is currently undergoing advanced stages of clinical evaluation for solid tumor therapy. In this work, we investigated possible interactions of this novel drug candidate with ABC drug efflux transporters and cytochrome P450 (CYP450) drug-metabolizing enzymes that participate in cancer multidrug resistance (MDR) and pharmacokinetic drug-drug interactions (DDIs). First, in accumulation experiments with various model substrates, we identified brivanib as an inhibitor of the ABCB1, ABCG2, and ABCC1 transporters. However, in subsequent combination studies employing 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide proliferation assays in both Madin-Darby canine kidney II (MDCKII) and A431 cellular models, only ABCG2 inhibition was revealed to be able to synergistically potentiate mitoxantrone effects. Advantageous to its possible use as MDR antagonist, brivanib's chemosensitizing properties were not impaired by activity of any of the MDR-associated ABC transporters, as observed in comparative viability assay in the MDCKII cell sublines. In incubation experiments with eight recombinant CYP450s, we found that brivanib potently inhibited CYP2C subfamily members and the CYP2B6 isoform. Finally, in induction studies, we demonstrated that brivanib upregulated ABCB1 and CYP1A2 messenger RNA levels in systemic cell models, although this interaction was not significantly manifested at a functional level. In conclusion, brivanib exhibits potential to cause clinically relevant pharmacokinetic DDIs and act as a modulator of ABCG2-mediated MDR. Our findings might be used as an important background for subsequent in vivo investigations and pave the way for the safe and effective use of brivanib in oncological patients.

Department of Pharmacology and Toxicology Faculty of Pharmacy in Hradec Kralove Charles University Akademika Heyrovskeho 1203 500 05 Hradec Kralove Czech Republic

Division of Biochemical Toxicology National Center for Toxicological Research U S FDA Jefferson Arkansas 72079 United States

Institute of Biotechnology Brandenburg University of Technology Cottbus Senftenberg Universitätsplatz 1 01968 Senftenberg Germany

See more in PubMed

Wilson L; Bhatnagar P; Townsend N. Comparing trends in mortality from cardiovascular disease and cancer in the United Kingdom, 1983-2013: joinpoint regression analysis. Popul. Health Metrics 2017, 15, No. 23. PubMed PMC

DeVita VT Jr.; Chu E. A history of cancer chemotherapy. Cancer Res. 2008, 68, 8643–8653. PubMed

Chou T; Finn RS Brivanib: a review of development. Future Oncol. 2012, 8, 1083–1090. PubMed

Llovet JM; Decaens T; Raoul JL; Boucher E; Kudo M; Chang C; Kang YK; Assenat E; Lim HY; Boige V; Mathurin P; Fartoux L; Lin DY; Bruix J; Poon RT; Sherman M; Blanc JF; Finn RS; Tak WY; Chao Y; Ezzeddine R; Liu D; Walters I; Park JW Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J. Clin. Oncol 2013, 31, 3509–3516. PubMed

Johnson PJ; Qin S; Park JW; Poon RT; Raoul JL; Philip PA; Hsu CH; Hu TH; Heo J; Xu J; Lu L; Chao Y; Boucher E; Han KH; Paik SW; Robles-Avina J; Kudo M; Yan L; Sobhonslidsuk A; Komov D; Decaens T; Tak WY; Jeng LB; Liu D; Ezzeddine R; Walters I; Cheng AL Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J. Clin. Oncol 2013, 31, 3517–3524. PubMed

Ye SL; Chen X; Yang J; Bie P; Zhang S; Liu F; Liu L; Zhou J; Dou K; Yip CS; Yang X. Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data. Tumour Biol. 2017, 39, No. 1010428317695030. PubMed

Szakács G; Váradi A; Özvegy-Laczka C; Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discovery Today 2008, 13, 379–393. PubMed

Zanger UM; Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther 2013, 138, 103–141. PubMed

Prueksaritanont T; Chu X; Gibson C; Cui D; Yee KL; Ballard J; Cabalu T; Hochman J. Drug-drug interaction studies: regulatory guidance and an industry perspective. AAPS J. 2013, 15, 629–645. PubMed PMC

Fletcher JI; Haber M; Henderson MJ; Norris MD ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer 2010, 10, 147–156. PubMed

Robey RW; Pluchino KM; Hall MD; Fojo AT; Bates SE; Gottesman MM Revisiting the role of ABC transporters in multidrug-resistant cancer. Nat. Rev. Cancer 2018, 18, 452–464. PubMed PMC

Michael M; Doherty MM Tumoral drug metabolism: overview and its implications for cancer therapy. J. Clin. Oncol 2005, 23, 205–229. PubMed

Rochat B. Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents. Curr. Cancer Drug Targets 2009, 9, 652–674. PubMed

Vadlapatla RK; Vadlapudi AD; Pal D; Mitra AK Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes. Curr. Pharm. Des 2013, 19, 7126–7140. PubMed

Bugde P; Biswas R; Merien F; Lu J; Liu DX; Chen M; Zhou S; Li Y. The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. Expert Opin. Ther. Targets 2017, 21, 511–530. PubMed

Kathawala RJ; Gupta P; Ashby CR Jr.; Chen ZS The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade. Drug Resist. Updates 2015, 18, 1–17. PubMed

Beretta GL; Cassinelli G; Pennati M; Zuco V; Gatti L. Overcoming ABC transporter-mediated multidrug resistance: The dual role of tyrosine kinase inhibitors as multitargeting agents. Eur. J. Med. Chem 2017, 142, 271–289. PubMed

Hofman J; Ahmadimoghaddam D; Hahnova L; Pavek P; Ceckova M; Staud F. Olomoucine II and purvalanol A inhibit ABCG2 transporter in vitro and in situ and synergistically potentiate cytostatic effect of mitoxantrone. Pharmacol. Res 2012, 65, 312–319. PubMed

Cihalova D; Hofman J; Ceckova M; Staud F. Purvalanol A, olomoucine II and roscovitine inhibit ABCB1 transporter and synergistically potentiate cytotoxic effects of daunorubicin in vitro. PLoS One 2013, 8, No. e83467. PubMed PMC

Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro. Biochem. Pharmacol 2015, 98, 465–472. PubMed

Cihalova D; Staud F; Ceckova M. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro. Cancer Chemother. Pharmacol 2015, 76, 105–116. PubMed

Sorf A; Hofman J; Kucera R; Staud F; Ceckova M. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro. Biochem. Pharmacol 2018, 154, 10–17. PubMed

Elkind NB; Szentpetery Z; Apati A; Ozvegy-Laczka C; Varady G; Ujhelly O; Szabo K; Homolya L; Varadi A; Buday L; Keri G; Nemet K; Sarkadi B. Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib). Cancer Res. 2005, 65, 1770–1777. PubMed

Xuan J; Chen S; Ning B; Tolleson WH; Guo L. Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity. Chem. Biol. Interact 2016, 255, 63–73. PubMed PMC

Herzog N; Hansen M; Miethbauer S; Schmidtke KU; Anderer U; Lupp A; Sperling S; Seehofer D; Damm G; Scheibner K; Kupper JH Primary-like human hepatocytes genetically engineered to obtain proliferation competence display hepatic differentiation characteristics in monolayer and organotypical spheroid cultures. Cell Biol. Int 2016, 40, 341–353. PubMed

Ramachandran SD; Vivares A; Klieber S; Hewitt NJ; Muenst B; Heinz S; Walles H; Braspenning J. Applicability of second-generation upcyte(R) human hepatocytes for use in CYP inhibition and induction studies. Pharmacol. Res. Perspect 2015, 3, No. e00161. PubMed PMC

Hofman J; Sorf A; Vagiannis D; Sucha S; Novotna E; Kammerer S; Kupper JH; Ceckova M; Staud F. Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance. Drug Metab. Dispos 2019, 47, 699–709. PubMed

Chou TC Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev 2006, 58, 621–681. PubMed

Mekhail T; Masson E; Fischer BS; Gong J; Iyer R; Gan J; Pursley J; Patricia D; Williams D; Ganapathi R. Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors. Drug Metab. Dispos 2010, 38, 1962–1966. PubMed PMC

EMA.

Szöllősi D; Rose-Sperling D; Hellmich UA; Stockner T. Comparison of mechanistic transport cycle models of ABC exporters. Biochim. Biophys. Acta, Biomembr 2018, 1860, 818–832. PubMed PMC

FDA. In Vitro Metabolism- and Transporter-Mediated Drug–Drug Interaction Studies Guidance for Industry. Clinical Pharmacology; CDER: Silver Spring, 2017.

Marathe PH; Kamath AV; Zhang Y; D’Arienzo C; Bhide R; Fargnoli J. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother. Pharmacol 2009, 65, 55–66. PubMed

Bayat Mokhtari R; Homayouni TS; Baluch N; Morgatskaya E; Kumar S; Das B; Yeger H. Combination therapy in combating cancer. Oncotarget 2017, 8, 38022–38043. PubMed PMC

Chang AY; Wang M. In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma. Anticancer Drugs 2013, 24, 251–259. PubMed

Lee F; Jure-Kunkel MN; Salvati ME Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence. Ther. Adv. Med. Oncol 2011, 3, 11–25. PubMed PMC

Alavi A; Hood JD; Frausto R; Stupack DG; Cheresh DA Role of Raf in vascular protection from distinct apoptotic stimuli. Science 2003, 301, 94–96. PubMed

Cygalova LH; Hofman J; Ceckova M; Staud F. Transplacental pharmacokinetics of glyburide, rhodamine 123, and BODIPY FL prazosin: effect of drug efflux transporters and lipid solubility. J. Pharmacol. Exp. Ther 2009, 331, 1118–1125. PubMed

Deng J; Shao J; Markowitz JS; An G. ABC transporters in multi-drug resistance and ADME-Tox of small molecule tyrosine kinase inhibitors. Pharm. Res 2014, 31, 2237–2255. PubMed

Miyoshi Y; Ando A; Takamura Y; Taguchi T; Tamaki Y; Noguchi S. Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int. J. Cancer 2002, 97, 129–132. PubMed

Syed S; Clemens PL; Lathers D; Kollia G; Dhar A; Walters I; Masson E. Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants. J. Clin. Pharmacol 2012, 52, 914–921. PubMed

Encorafenib Acts as a Dual-Activity Chemosensitizer through Its Inhibitory Effect on ABCC1 Transporter In Vitro and Ex Vivo

Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study

Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo

Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance

Ensartinib (X-396) Effectively Modulates Pharmacokinetic Resistance Mediated by ABCB1 and ABCG2 Drug Efflux Transporters and CYP3A4 Biotransformation Enzyme